Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease.

ABSTRACT:

Importance

While clinical disease stages remained largely unchanged in the 2024 update of the Alzheimer disease (AD) criteria, tau-positron emission tomography (PET) was introduced as a core biomarker and its spatial extent was incorporated into the revised biological stages of the disease. It is important to consider both the clinical and the biological stages and understand their discrepancies.

Objective

To compare individuals who have discrepant biological and clinical stages with those who have congruent stages in terms of copathologies, comorbidities, and demographics.

Design, setting, and participants

Participants were from the Swedish BioFINDER-2 (inclusion from 2017 through 2023) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) (inclusion from 2015 t

SUBMITTER: Pichet Binette A 

PROVIDER: S-EPMC12090069 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature